No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis-Reference-Cited by-同舟云学术

No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis

Published:2023-10 Issue:5 Volume:13 Page:
ISSN:2163-0402
Container-title:Neurology Clinical Practice
language:en
Short-container-title:Neur Clin Pract

Author:

Kister Ilya¹,Oh Cheongeun¹^ORCID,Douglas Elizabeth A.¹^ORCID,Bacon Tamar E.¹^ORCID,O'Shea Isabella L.¹^ORCID,Parrotta Erica H.¹^ORCID,Bouley Andrew¹^ORCID,Lathi Ellen¹,Katz Joshua¹^ORCID

Affiliation:

1. NYU Multiple Sclerosis Comprehensive Care Center (IK, TEB), Department of Neurology; Department of Population Health (CO), NYU Grossman School of Medicine, New York; The Elliot Lewis Center for Multiple Sclerosis Care (EAD, ILOS, AB, EL, JK), Wellesley, MA; and St. Peter's MS and Headache Center (EHP), Albany, NY.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Link

https://www.neurology.org/doi/pdfdirect/10.1212/CPJ.0000000000200185

Reference35 articles.

1. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

2. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

3. Wagner E. 2022. Accessed May 3 2022. mymsteam.com/resources/what-is-the-crap-gap-between-ms-infusions

4. The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis

5. End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial;Journal of the Neurological Sciences;2024-07

2. Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis;Diseases;2024-06-16

3. The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis;Journal of Neurology;2024-05-23

4. The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-04

5. Ocrelizumab - what we know, what we can improve now, what we can improve in the future;Neurologie pro praxi;2024-03-06